US FDA approves Lupkynis (voclosporin)

More great news for people with lupus! The U.S. Food and Drug Administration (FDA) has approved Lupkynis™ (voclosporin) to treat lupus nephritis (lupus-related kidney disease) in adults when used in combination with a background immunosuppressive therapy regimen. Lupkynis is the second new therapy authorized to treat this potentially life-threatening complication of lupus. Developed by Aurinia…

US FDA approve Benlysta

GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA The U.S. Food and Drug Administration (FDA) in late December 2020 approved Benlysta® to treat lupus nephritis (lupus-related kidney disease) in adults. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. Another milestone, this new…

Phase 3 Trial – Benlysta

Phase 3 Trial Finds Benlysta Significantly Improves Kidney Response in People with Lupus Nephritis UPDATE 16/09/2020 In new results on the international phase 3 clinical trial (BLISS-LN) of the drug Benlysta (belimumab), researchers found that Benlysta reduced the risk of worsening kidney function during the study by almost 50%, compared with standard therapy alone. The…

Inactivity, Isolation and Impact on Daily Life are Top Concerns for People Living with Lupus

World Lupus Federation issues global report for World Lupus Day highlighting the life-altering effects of lupus and the challenges people with lupus face every day. WASHINGTON, May 9, 2017 /PRNewswire-USNewswire/ — Almost half (43%) of people living with lupus responding to a recent poll* indicated that they worry the most about physical inactivity and social isolation…

Research Improving Clinical Trial Design

Researchers face multiple obstacles that can hinder their ability to show whether a potential lupus treatment works or may be better than a current treatment. Years of disappointing results in lupus drug development demonstrates that a different approach is needed. In 2009, the Lupus Foundation of America established the LFA Collective Data Analysis Initiative (LFA…

12th International Conference on SLE

Lupus Education Conference to Provide Updates on Developments in Disease Research and Treatment for Patients, Families and Caregivers Global experts shared the latest developments in Lupus diagnosis and treatment. Lupus Association NSW Inc. was a proud partner and delivered this fantastic opportunity to patients, members and supporters, held last March 26-29, 2017 at the Melbourne…